HCM – HUTCHMED (China) Limited
HUTCHMED (China) LimitedHCM
$16.11Name : HUTCHMED (China) Limited
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $2,753,778,944.00
EPSttm : -0.25
HUTCHMED (China) Limited
$16.11
5.09%$0.78Float Short %
0.24
Margin Of Safety %
Put/Call OI Ratio
0.82
EPS Next Q Diff
EPS Last/This Y
EPS This/Next Y
0.64
Price
16.12
Target Price
25.61
Analyst Recom
1.28
Performance Q
-4.28
Relative Volume
1.81
Beta
0.81
Ticker: HCM
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-01-23 | HCM | 13.63 | 0.97 | 3.00 | 323 |
| 2025-01-24 | HCM | 13.57 | 0.97 | 3.00 | 323 |
| 2025-01-27 | HCM | 13.63 | 0.97 | 3.00 | 323 |
| 2025-01-28 | HCM | 13.5 | 0.98 | 0.00 | 325 |
| 2025-01-29 | HCM | 13.61 | 0.98 | 0.00 | 325 |
| 2025-01-30 | HCM | 13.85 | 0.97 | 999.99 | 327 |
| 2025-01-31 | HCM | 13.53 | 0.97 | 999.99 | 327 |
| 2025-02-03 | HCM | 13.23 | 0.98 | 0.00 | 328 |
| 2025-02-04 | HCM | 13.54 | 0.97 | 0.00 | 329 |
| 2025-02-05 | HCM | 13.9 | 0.97 | 0.00 | 329 |
| 2025-02-06 | HCM | 13.97 | 0.96 | 0.00 | 330 |
| 2025-02-07 | HCM | 13.25 | 0.96 | 0.00 | 331 |
| 2025-02-10 | HCM | 13.46 | 0.93 | 0.00 | 336 |
| 2025-02-11 | HCM | 13.2 | 0.92 | 999.99 | 338 |
| 2025-02-12 | HCM | 13.08 | 0.92 | 999.99 | 338 |
| 2025-02-13 | HCM | 13.22 | 0.92 | 999.99 | 338 |
| 2025-02-14 | HCM | 13.79 | 0.86 | 0.00 | 327 |
| 2025-02-18 | HCM | 13.73 | 0.85 | 0.00 | 329 |
| 2025-02-19 | HCM | 14.82 | 0.83 | 0.00 | 332 |
| 2025-02-20 | HCM | 15.32 | 0.83 | 0.00 | 333 |
| 2025-02-21 | HCM | 16.12 | 0.82 | 0.00 | 336 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-01-23 | HCM | 13.60 | - | 226.6 | -0.24 |
| 2025-01-24 | HCM | 13.56 | - | 223.1 | -0.24 |
| 2025-01-27 | HCM | 13.61 | - | 222.5 | -0.24 |
| 2025-01-28 | HCM | 13.47 | - | 223.4 | -0.24 |
| 2025-01-29 | HCM | 13.61 | - | 222.3 | -0.24 |
| 2025-01-30 | HCM | 13.81 | - | 222.3 | -0.24 |
| 2025-01-31 | HCM | 13.55 | - | 224.8 | -0.24 |
| 2025-02-03 | HCM | 13.21 | - | 224.8 | -0.24 |
| 2025-02-04 | HCM | 13.52 | - | 222.2 | -0.24 |
| 2025-02-05 | HCM | 13.89 | - | 221.5 | -0.24 |
| 2025-02-06 | HCM | 13.99 | - | 34.2 | -0.24 |
| 2025-02-07 | HCM | 13.22 | - | 38.1 | -0.24 |
| 2025-02-10 | HCM | 13.42 | - | 27.5 | -0.24 |
| 2025-02-11 | HCM | 13.21 | - | 30.9 | -0.24 |
| 2025-02-12 | HCM | 13.09 | - | 31.7 | -0.24 |
| 2025-02-13 | HCM | 13.22 | - | 28.7 | -0.24 |
| 2025-02-14 | HCM | 13.80 | - | 26.0 | -0.24 |
| 2025-02-18 | HCM | 13.73 | - | 28.8 | -0.24 |
| 2025-02-19 | HCM | 14.83 | - | 23.3 | -0.24 |
| 2025-02-20 | HCM | 15.36 | - | 25.6 | -0.24 |
| 2025-02-21 | HCM | 16.12 | - | 25.0 | -0.24 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-01-23 | HCM | 0.00 | -24.25 | 0.28 |
| 2025-01-24 | HCM | 0.00 | -24.25 | 0.28 |
| 2025-01-27 | HCM | 0.00 | -24.27 | 0.28 |
| 2025-01-28 | HCM | 0.00 | -24.27 | 0.24 |
| 2025-01-29 | HCM | 0.00 | -24.27 | 0.24 |
| 2025-01-30 | HCM | 0.00 | -24.27 | 0.24 |
| 2025-01-31 | HCM | 0.00 | -24.27 | 0.24 |
| 2025-02-03 | HCM | 0.00 | -23.93 | 0.24 |
| 2025-02-04 | HCM | 0.00 | -23.93 | 0.24 |
| 2025-02-05 | HCM | 0.00 | -23.93 | 0.24 |
| 2025-02-06 | HCM | 0.00 | -23.93 | 0.24 |
| 2025-02-07 | HCM | 0.00 | -23.93 | 0.24 |
| 2025-02-10 | HCM | 0.00 | -23.36 | 0.24 |
| 2025-02-11 | HCM | 0.00 | -23.36 | 0.24 |
| 2025-02-12 | HCM | 0.00 | -23.36 | 0.24 |
| 2025-02-13 | HCM | 0.00 | -23.36 | 0.24 |
| 2025-02-14 | HCM | 0.00 | -23.36 | 0.24 |
| 2025-02-18 | HCM | 0.00 | -24.17 | 0.24 |
| 2025-02-19 | HCM | 0.00 | -24.17 | 0.24 |
| 2025-02-20 | HCM | 0.00 | -24.17 | 0.24 |
| 2025-02-21 | HCM | 0.00 | -24.17 | 0.24 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
Avg. EPS Est. Next Quarter
Insider Transactions
Institutional Transactions
-24.17
Beta
0.81
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
41
Growth Score
44
Sentiment Score
80
Actual DrawDown %
63.3
Max Drawdown 5-Year %
-82.2
Target Price
25.61
P/E
Forward P/E
7.97
PEG
P/S
4.55
P/B
3.79
P/Free Cash Flow
EPS
-0.25
Average EPS Est. Cur. Y
-0.24
EPS Next Y. (Est.)
0.4
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-7.03
Relative Volume
1.81
Return on Equity vs Sector %
-24.9
Return on Equity vs Industry %
-13.5
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.01
EBIT Estimation
25
HUTCHMED (China) LimitedSector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 1970
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
stock quote shares HCM – HUTCHMED (China) Limited Stock Price stock today
news today HCM – HUTCHMED (China) Limited stock forecast ,stock prediction 2023 2024 2025
marketwatch HCM – HUTCHMED (China) Limited yahoo finance google finance
stock history HCM – HUTCHMED (China) Limited invest stock market
stock prices HCM premarket after hours
ticker HCM fair value insiders trading